Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Testosterone undecanoate oral - TesoRx

Next Previous
Drug Profile

Testosterone undecanoate oral - TesoRx

Alternative Names: Low-T therapy - TesoRx; Oral TRT therapy - TesoRx; Testosterone replacement therapy - TesoRx; THG 1001; TSX-011; TSX-049

Latest Information Update: 17 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TesoRx
  • Developer ASKA Pharmaceutical; TesoRx
  • Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hypogonadism

Most Recent Events

  • 21 Oct 2020 Preclinical trials in Hypogonadism (TSX 049) in USA (PO) (TesoRx pipeline, October 2020)
  • 21 Oct 2020 NDR batch#17: Updated intro, dev table, added FET for planned P-I/II for TSX-049 [discontinued P-I/II trial for TSX 011 as it was terminated and candidate does not appear in company pipeline; added preclinical dev line for TSX 049 on the basis of pipeline]
  • 24 Sep 2020 Pharmacokinetics data from a preclinical study in canines for Hypogonadism released by TesoRx
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top